Reborna Biosciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $5.33M

  • Investors
  • 9

Reborna Biosciences General Information

Description

Developer of a drug discovery technology designed to demonstrate fundamental treatment effects through the normalization of RNA function. The company's technology creates small-molecule drugs with an affinity for ribonucleic acid using the natural three-dimensional structure of RNA in vivo, enabling physicians to treat genetically rare diseases.

Contact Information

Website
www.rebornabiosciences.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 26-1, Muraoka-Higashi 2-chome
  • Shonan Health Innovation Park, Kanagawa
  • Fujisawa, Kanagawa 251-8555
  • Japan
+81
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 26-1, Muraoka-Higashi 2-chome
  • Shonan Health Innovation Park, Kanagawa
  • Fujisawa, Kanagawa 251-8555
  • Japan
+81

Reborna Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reborna Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 25-Jun-2025 $5.33M Completed Pre-Clinical Trials
5. Secondary Transaction - Private 18-Feb-2024 Completed Pre-Clinical Trials
4. Later Stage VC (Series C) 25-May-2023 Completed Pre-Clinical Trials
3. Later Stage VC (Series C) 14-Oct-2021 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 01-Dec-2019 $4.13M $6.47M Completed Startup
1. Seed Round 25-Jun-2018 $2.33M $2.33M Completed Startup
To view Reborna Biosciences’s complete valuation and funding history, request access »

Reborna Biosciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
class D
class C
Class B
Class A Voting Rights Stocks 1,778 $173.09 $173.09 1x $173.09 2.34%
Class A shares 8,472 $173.09 $173.09 1x $173.09 11.15%
To view Reborna Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Reborna Biosciences Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Reborna Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2021117122-A1 Prophylactic or therapeutic agent for lysosomal acid lipase deficiency syndrome Inactive 10-Dec-2019
JP-2020000097-A Agent for preventing or treating lysosomal acid lipase deficiency Pending 27-Jun-2018
JP-7427252-B2 Preventive or therapeutic agents for spinal muscular atrophy Active 27-Jun-2018
JP-WO2020004594-A1 Preventive or therapeutic agents for spinal muscular atrophy Active 27-Jun-2018
AU-2019293757-A1 Prophylactic or therapeutic agent for spinal muscular atrophy Active 27-Jun-2018 C07D487/04
To view Reborna Biosciences’s complete patent history, request access »

Reborna Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reborna Biosciences Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gogin Capital PE/Buyout Minority
ICMG Partners Venture Capital Minority
UntroD Venture Capital Minority
Yokohama Capital Venture Capital Minority
Angel Bridge Angel Group Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Reborna Biosciences FAQs

  • When was Reborna Biosciences founded?

    Reborna Biosciences was founded in 2018.

  • Where is Reborna Biosciences headquartered?

    Reborna Biosciences is headquartered in Fujisawa, Japan.

  • What is the size of Reborna Biosciences?

    Reborna Biosciences has 12 total employees.

  • What industry is Reborna Biosciences in?

    Reborna Biosciences’s primary industry is Drug Discovery.

  • Is Reborna Biosciences a private or public company?

    Reborna Biosciences is a Private company.

  • What is the current valuation of Reborna Biosciences?

    The current valuation of Reborna Biosciences is .

  • What is Reborna Biosciences’s current revenue?

    The current revenue for Reborna Biosciences is .

  • How much funding has Reborna Biosciences raised over time?

    Reborna Biosciences has raised $18.5M.

  • Who are Reborna Biosciences’s investors?

    Gogin Capital, ICMG Partners, UntroD, Yokohama Capital, and Angel Bridge are 5 of 9 investors who have invested in Reborna Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process